首页> 外国专利> Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration

Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration

机译:用于小剂量给药的高浓度同种异体选择抗体的稳定组成

摘要

Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.
机译:公开了用于皮下,肌内,透皮或其他局部(区域)给药的高浓度抗体或免疫球蛋白制剂的方法,组合物和用途,其体积小于3ml,小于2ml或小于1ml。优选地,该制剂包含高浓度制剂(HCF)缓冲液,其包含在约5.2的pH下的磷酸盐,柠檬酸盐,聚山梨酯80和甘露醇。该制剂更优选包含至少100、150、200、250mg / ml或300mg / ml的抗体。制备高浓度制剂的方法包括超滤和渗滤以浓缩抗体并将培养基换为HCF缓冲液。其他实施方案涉及非G1m1(nG1m1)同种型抗体的使用,例如G1m3和/或nG1m1,2抗体。与G1m1抗体相比,nG1m1抗体显示出降低的免疫原性。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号